GSK plc (NYSE:GSK) Receives $43.25 Average PT from Analysts

GSK plc (NYSE:GSK) has been assigned a consensus rating of “Moderate Buy” from the nine brokerages that are currently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and three have given a strong buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $43.25.

Several analysts have issued reports on the company. StockNews.com downgraded GSK from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 21st. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and reduced their price target for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Finally, Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st.

GSK Price Performance

Shares of GSK opened at $37.67 on Friday. The stock has a 50 day simple moving average of $34.10 and a 200 day simple moving average of $37.60. GSK has a 52-week low of $31.72 and a 52-week high of $45.92. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. The firm has a market capitalization of $78.07 billion, a PE ratio of 24.46, a P/E/G ratio of 1.38 and a beta of 0.64.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a net margin of 7.97% and a return on equity of 50.62%. Sell-side analysts predict that GSK will post 3.92 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Indiana Trust & Investment Management Co raised its stake in shares of GSK by 200.0% during the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock worth $25,000 after purchasing an additional 500 shares in the last quarter. Eastern Bank acquired a new position in GSK during the third quarter worth $26,000. Crews Bank & Trust bought a new stake in GSK during the fourth quarter worth $26,000. ST Germain D J Co. Inc. lifted its stake in GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 522 shares during the last quarter. Finally, Sunbelt Securities Inc. grew its position in shares of GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after acquiring an additional 302 shares during the period. 15.74% of the stock is owned by institutional investors and hedge funds.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.